Chinese Pharma Advances AI-Discovered Drug to Phase III Trials
96Stats · x · 2026-07-14
A Chinese pharmaceutical company has advanced a lung cancer drug—entirely targeted and molecularly designed by AI—into Phase III clinical trials (involving 320名患者).
Additionally, the company invested up to 1.75 亿美元 in developing another brain disease drug based on an AI-identified mechanism. This indicates a shift in Chinese pharma procurement models: moving from simply subscribing to AI software tools to directly purchasing AI-generated biological hypotheses and outcomes.
Related event: AI-Discovered Drug Enters Phase III Trials in China(2 posts)→
More from Research
- Navier-Stokes, Riemann, P vs NP: what this week's math buzzwords mean for you — koltregaskes · 2026-09-11
- Fruit fly connectome LLM weights land on Hugging Face, transformers-compatible — ngxson · 2026-09-11
- Fruit fly brain as an LLM: connectome-driven language model demo goes live — ngxson · 2026-09-11
- Harry Collins: LLMs can't do frontier science because they can't invent new language — whoamisri · 2026-09-11
- The Waymo effect: how AI is quietly making research less collaborative — JohnHammersley · 2026-09-11
- Causal-only attention for non-generative tasks is wasteful, argues HF engineer — antoine_chaffin · 2026-09-11